Agenus to Present at the American Society of Clinical Oncology 2023 Annual Meeting
April 26 2023 - 10:35AM
Business Wire
- Oral presentation on Phase 2 trial evaluating
balstilimab/zalifrelimab plus standard of care in advanced
sarcoma
- Poster discussion on Phase 1 trial investigating AGEN2373
monotherapy in advanced solid tumors
Agenus (Nasdaq: AGEN), a leading immuno-oncology company
specializing in immunological agents for cancer and infectious
diseases, today announced plans to present clinical data at the
American Society of Clinical Oncology (ASCO) 2023 Annual Meeting,
to be held June 2-6 in Chicago, IL.
Data from a single-arm, open-label Phase 2 study of balstilimab
(PD-1 antagonist) and zalifrelimab (first generation CTLA-4
antagonist) plus doxorubicin in patients with advanced sarcomas
will be presented at an oral session on Monday, June 5 from 11:30am
- 2:30pm CDT.
Complete results from the monotherapy arm of the first-in-human
dose escalation study of AGEN2373 (CD137 agonist) in patients with
advanced solid tumors will be presented at a poster discussion on
Saturday, June 3rd from 3:00pm - 4:30pm CDT.
Presentation Details:
Abstract Title: A single-arm, open-label phase 2 trial of
doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with
balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic
soft tissue sarcomas Abstract #: 403784
Presenting Author: Dr. Breelyn Wilky, MD, Director of
Sarcoma Medical Oncology, Deputy Associate Director for Clinical
Research, University of Colorado Medicine Session
Title: Oral Abstract Session - Sarcoma Session Date
and Time: 6/5/2023, 11:30am – 2:30pm CDT
Abstract Title: A Phase 1 Study of AGEN2373, a Novel
CD137 Agonist Antibody Designed to Avoid Hepatoxicity, in Patients
with Advanced Solid Tumors (NCT 04121676) Abstract #:
2524 Poster Board #: 366 Presenting
Author: Dr. Minal Barve, MD, Executive Medical Director and
Chief Medical Officer, Mary Crowley Cancer Research Poster
Discussion Session: Developmental Therapeutics -
Immunotherapy Poster Session Display Date and Time:
6/3/2023, 8:00am – 11:00am CDT Poster Discussion Session
Date and Time: 6/3/2023, 3:00pm – 4:30pm CDT
The complete abstracts will be available on May 25th, 2023, at
5:00pm ET. Data presented at the conference will be available to
view in the Publications section of the Agenus website
(https://agenusbio.com/publications) following the ASCO
Conference.
About Balstilimab
Balstilimab is a novel, fully human monoclonal immunoglobulin G4
(IgG4) designed to block PD-1 (programmed cell death protein 1)
from interacting with its ligands PD-L1 and PD-L2. PD-1 is a
negative regulator of immune activation that is considered a
foundational target within the immuno-oncology market. Agenus is
developing balstilimab as a backbone agent for combination trials
within its portfolio, as well as supplying drug to collaborators to
enable novel combinations with external agents.
About Zalifrelimab
Zalifrelimab is a novel, fully human monoclonal immunoglobulin G1
(IgG1) designed to block CTLA-4 (cytotoxic T-lymphocyte associated
antigen 4) from interacting with its ligands CD80 and CD86.
Clinical trials have shown its efficacy in multiple indications,
including a Phase 2 study in cervical cancer where it demonstrated
robust activity in combination with balstilimab (O’Malley et al.
JCO 2022).
About AGEN2373 AGEN2373 is a
novel anti-CD137 agonist that has been designed to activate T and
NK cells while mitigating liver toxicities common to the CD137
target class. CD137 (4-1BB) is an activating receptor expressed on
T and NK cells. Upon binding to CD137, AGEN2373 is designed to
stimulate the growth and activation of cytotoxic T and NK cells,
triggering a lasting memory response to cancer. AGEN2373 binds to a
unique epitope designed to achieve this response specifically
within the tumor microenvironment. This selective binding is
designed to avoid serious side effects associated with CD137
activation in the liver that have been reported by competitor
molecules. AGEN2373 has demonstrated preliminary clinical activity
and has been well tolerated by patients without signs of liver
toxicity (Tolcher et al. ASCO 2021).
About Agenus Agenus is a
clinical-stage immuno-oncology company focused on the discovery and
development of therapies that engage the body's immune system to
fight cancer and infections. The Company's vision is to expand the
patient populations benefiting from cancer immunotherapy by
pursuing combination approaches that leverage a broad repertoire of
antibody therapeutics, adoptive cell therapies (through its
subsidiary MiNK Therapeutics), and adjuvants (through its
subsidiary SaponiQx). The Company is equipped with a suite of
antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and Twitter.
Forward Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements relating to the use of
AGEN2373, for instance, statements regarding therapeutic benefit
and efficacy, mechanism of action (including validation of
mechanism of action), potency, durability, and safety profile
(including the absence of specific toxicities) of the Company’s
therapeutic candidates; and any other statements containing the
words "may," "believes," "expects," "anticipates," "hopes,"
"intends," "plans," "forecasts," "estimates," "will," “establish,”
“potential,” “superiority,” “best in class,” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include, among others, the factors
described under the Risk Factors section of our most recent
Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed
with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230426005694/en/
Agenus Inc. Zack Armen Head of Investor Relations 917-362-1370
zack.armen@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024